### Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia: Feasibility Analysis

First published: 03/12/2024

**Last updated:** 23/10/2025





#### Administrative details

# EU PAS number EUPAS1000000387 Study ID 1000000387 DARWIN EU® study No Study countries Canada

#### Study description

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a relatively novel class of drugs used in the treatment of heterozygous familial hypercholesterolemia (hereafter, FH). However, data are limited on the real-

world use and effectiveness of PCSK9i for FH in Canada. The aims of this study are 1) to determine the percentage of patients with FH achieving Canadian public drug plan treatment goals for PCSK9i, and 2) to estimate the incidence of major adverse cardiovascular events among patients with FH who are prescribed PCSK9i. Using administrative healthcare data from the provinces of Alberta, British Columbia, and Ontario, we will identify patients who began treatment with a PCSK9i (alirocumab or evolocumab) between 2015 and 2023. Because provincial drug plan coverage for PCSK9i requires that patients have a diagnosis of FH and because diagnoses of FH are not specifically coded in physician service claims, we will assume that patients with publicly paid claims have a diagnosis of FH, acknowledging that some patients may be misclassified. Patients with claims for PCSK9i that are reimbursed by private insurers may or may not have FH. Patient characteristics at the time of PCSK9i initiation will be described. We will determine the percentage of patients achieving the public drug plans' recommended treatment goal of at least 40% reduction in LDL-C levels during treatment with PCSK9i. The incidence of major adverse cardiovascular events during treatment will be estimated to support assessment of the feasibility of future observational studies of PCSK9i.

#### **Study status**

Ongoing

#### Research institutions and networks

**Institutions** 

Lady Davis Institute

First published: 01/02/2024

**Last updated:** 01/02/2024



#### University of British Columbia

First published: 01/02/2024

Last updated: 01/02/2024



University of Alberta, Edmonton, Canada ICES, Toronto, Canada

#### **Networks**

Canadian Network for Observational Drug Effect Studies (CNODES) and Alberta Drug and Technology Evaluation Consortium (ADTEC)

#### Contact details

Study institution contact
Michael Paterson cc@cnodes.ca

Study contact

cc@cnodes.ca

#### **Primary lead investigator**

Michael Paterson

**Primary lead investigator** 

#### Study timelines

#### Date when funding contract was signed

Planned: 08/08/2024

Actual: 08/08/2024

#### Study start date

Planned: 08/08/2024

Actual: 08/08/2024

#### **Date of final study report**

Planned: 14/04/2025

#### Sources of funding

Other

#### More details on funding

CNODES and ADTEC are collaborating core network partners of CoLab funded for query-related activity by Canada's Drug Agency (CNODES CDA grant number C222 360).

#### Regulatory

Was the study required by a regulatory body? No
Is the study required by a Risk Management Plan (RMP)?  Not applicable
Methodological aspects
Study type
Study type list
Study topic: Human medicinal product
Study type: Non-interventional study
Scope of the study:
Drug utilisation
Feasibility analysis
Safety study (incl. comparative)
Data collection methods:

#### Study design:

Descriptive cohort study

Secondary use of data

#### Main study objective:

The main objectives are:

- 1. To determine the percentage of patients with FH who are achieving the public drug plans' recommended treatment goal of at least 40% reduction in LDL-C during treatment with PCSK9i.
- 2. To estimate the incidence of major adverse cardiovascular events among patients with FH who are prescribed PCSK9i.

#### Study Design

#### Non-interventional study design

Cohort

#### Study drug and medical condition

#### Name of medicine

**PRALUENT** 

REPATHA

#### Study drug International non-proprietary name (INN) or common name

**ALIROCUMAB** 

**EVOLOCUMAB** 

#### **Anatomical Therapeutic Chemical (ATC) code**

(C10AX13) evolocumab

evolocumab

(C10AX14) alirocumab

alirocumab

#### Additional medical condition(s)

Heterozygous Familial Hypercholesterolemia

#### Population studied

#### Short description of the study population

The study population will include all patients aged 10 years or older (66 years or older in Ontario) who began treatment with a PCSK9i in the study provinces between April 1, 2015 (or the date of the first claim for PCSK9i in each province) and March 31, 2023.

#### **Age groups**

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adult and elderly population (≥18 years)

#### **Estimated number of subjects**

20000

#### Study design details

#### Setting

Using administrative healthcare data from the provinces of Alberta, British Columbia, and Ontario, we will identify patients who began treatment with a PCSK9i (alirocumab or evolocumab) between 2015 and 2023. Because provincial drug plan coverage for PCSK9i requires that patients have a diagnosis of FH and because diagnoses of FH are not specifically coded in physician service claims, we will assume that patients with publicly paid claims have a diagnosis of FH, acknowledging that some patients may be misclassified.

Patients with claims for PCSK9i that are reimbursed by private insurers may or may not have FH. To ensure patients are new users, we will require a minimum of 365 days of data availability with no prescription for PCSK9i. Cohort entry will be defined as the date of the first dispensing of a PCSK9i. For the purposes of cardiovascular outcome assessment, patients will be followed from the date of cohort entry to the first of: a major adverse cardiovascular event, treatment discontinuation, loss of health insurance, death, or end of the study period.

#### **Outcomes**

We will study 4 sets of measures:

- 1. Patient characteristics at cohort entry (sociodemographic and clinical characteristics)
- 2. Duration of PCSK9i therapy
- 3. Attainment of LDL-C treatment targets: Among patients for whom the required laboratory data are available, we will determine the percentage who:
- a. Achieve the public drug plan's recommended 40% reduction in LDL-C within 8 weeks of PCSK9i initiation (sensitivity analyses may be performed using different time frames)
- b. Maintain the public drug plans' recommended 40% reduction in LDL-C during PCSK9i therapy (although the drug plans recommend a 40% reduction in LDL-C within 8 weeks of PCSK9i initiation, sensitivity analyses may evaluate additional time frames that better reflect usual testing practice)
- c. Achieve the 2021 Canadian Cardiovascular Society post-treatment absolute LDL-C thresholds for primary prevention (no previous atherosclerotic cardiovascular disease (ASCVD)) or secondary prevention (previous ASCVD) within 8 of PCSK9i initiation

- d. Achieve specific LDL-C thresholds within 8 weeks of PCSK9i initiation for primary and secondary prevention patients
- 4. Incidence of major adverse cardiovascular events (MACE) overall and at 1 year: defined a composite outcome consisting of myocardial infarction, ischemic stroke, cardiovascular procedure (receipt of any of a coronary artery bypass graft, percutaneous coronary intervention, or carotid endarterectomy), or cardiovascular death (using the algorithm previously validated by Lix et al. 2021).

The incidence of MACE during treatment will be estimated to support assessment of the feasibility of future observational studies of PCSK9i.

#### Data analysis plan

Analyses will be completed in each provincial database with measures pooled cross-provincially as appropriate. First, patient characteristics at the time of PCSK9i initiation will be described. Second, the mean and median duration of PCSK9i therapy will be estimated, from the date of treatment initiation to the date of discontinuation. Third, the percentage of patients achieving the LDL-C treatment targets (described above) will be determined. Fourth, the crude and age- and sex-standardized incidence rate and corresponding 95% confidence intervals of MACE will be estimated both overall (i.e., at any time during follow-up) and at 1 year of follow-up among all PCSK9i initiators and among the subset with and without a history of these events, and those with and without a history of ASCVD. MACE will also be computed by subgroups. Last, a sensitivity analysis will be conducted for the attainment of LDL-C targets in the subset of patients with baseline measures in a shorter timeframe preceding PCSK9i initiation.

#### **Documents**

Link to project page on CNODES website.

Major adverse cardiovascular events definition

Cardiovascular death algorithm definition

#### Data management

#### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

#### Data sources

#### Data source(s), other

Provincial administrative health databases

#### **Data sources (types)**

Administrative healthcare records (e.g., claims)

Laboratory tests and analyses

Pharmacy dispensing records

Population registry

#### Use of a Common Data Model (CDM)

#### **CDM** mapping

No

#### Data quality specifications

## Unknown Check completeness Unknown

#### **Check stability**

**Check conformance** 

Unknown

#### **Check logical consistency**

Unknown

#### Data characterisation

#### **Data characterisation conducted**

No